152 related articles for article (PubMed ID: 24367063)
1. The relationship between functional health literacy and the use of the health system by diabetics in Switzerland.
Franzen J; Mantwill S; Rapold R; Schulz PJ
Eur J Public Health; 2014 Dec; 24(6):997-1003. PubMed ID: 24367063
[TBL] [Abstract][Full Text] [Related]
2. Utilization and costs for compliant patients initiating therapy with pioglitazone or rosiglitazone versus insulin in a Medicaid fee-for-service population.
Kalsekar I; Iyer S; Mody R; Rajagopalan R; Kavookjian J
J Manag Care Pharm; 2006 Mar; 12(2):121-9. PubMed ID: 16515370
[TBL] [Abstract][Full Text] [Related]
3. Multimorbidity, health care utilization and costs in an elderly community-dwelling population: a claims data based observational study.
Bähler C; Huber CA; Brüngger B; Reich O
BMC Health Serv Res; 2015 Jan; 15():23. PubMed ID: 25609174
[TBL] [Abstract][Full Text] [Related]
4. Economic Impact of Treatment Duration and Persistence with Basal Insulin in Previously Insulin-Naive Users.
Kalirai S; Duan R; Liu D; Reed BL
J Manag Care Spec Pharm; 2017 Mar; 23(3):327-336. PubMed ID: 28230446
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness and cost-utility of insulin glargine compared with NPH insulin based on a 10-year simulation of long-term complications with the Diabetes Mellitus Model in patients with type 2 diabetes in Switzerland.
Brändle M; Azoulay M; Greiner RA
Int J Clin Pharmacol Ther; 2007 Apr; 45(4):203-20. PubMed ID: 17474539
[TBL] [Abstract][Full Text] [Related]
6. Health Literacy, Health Care Utilization, and Direct Cost of Care Among Linguistically Diverse Patients with Type 2 Diabetes Mellitus.
Doyle G; Gibney S; Quan J; Martensen U; Schillinger D
Health Lit Res Pract; 2017 Jul; 1(3):e116-e126. PubMed ID: 31294257
[TBL] [Abstract][Full Text] [Related]
7. Dosing of U-100 insulin and associated outcomes among Medicare enrollees with type 1 or type 2 diabetes.
Eby EL; Van Brunt K; Brusko C; Curtis B; Lage MJ
Clin Interv Aging; 2015; 10():991-1001. PubMed ID: 26124652
[TBL] [Abstract][Full Text] [Related]
8. Resource utilization and costs associated with using insulin therapy within a newly diagnosed type 2 diabetes mellitus population.
Bell K; Parasuraman S; Raju A; Shah M; Graham J; Denno M
J Manag Care Spec Pharm; 2015 Mar; 21(3):220-8a. PubMed ID: 25726031
[TBL] [Abstract][Full Text] [Related]
9. Retrospective database analysis of the impact of prior authorization for type 2 diabetes medications on health care costs in a Medicare Advantage Prescription Drug Plan population.
Bergeson JG; Worley K; Louder A; Ward M; Graham J
J Manag Care Pharm; 2013 Jun; 19(5):374-84. PubMed ID: 23697475
[TBL] [Abstract][Full Text] [Related]
10. Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population.
Grabner M; Peng X; Geremakis C; Bae J
J Manag Care Spec Pharm; 2015 Dec; 21(12):1204-12. PubMed ID: 26679969
[TBL] [Abstract][Full Text] [Related]
11. Health literacy and quality of care of patients with diabetes: A cross-sectional analysis.
Zuercher E; Diatta ID; Burnand B; Peytremann-Bridevaux I
Prim Care Diabetes; 2017 Jun; 11(3):233-240. PubMed ID: 28292571
[TBL] [Abstract][Full Text] [Related]
12. Disease-related and all-cause health care costs of elderly patients with gout.
Wu EQ; Patel PA; Yu AP; Mody RR; Cahill KE; Tang J; Krishnan E
J Manag Care Pharm; 2008 Mar; 14(2):164-75. PubMed ID: 18331118
[TBL] [Abstract][Full Text] [Related]
13. Healthcare utilization changes in relation to treatment intensification with insulin aspart in patients with type 2 diabetes. Data from a large US managed-care organization.
Aagren M; Luo W; Moës E
J Med Econ; 2010 Mar; 13(1):16-22. PubMed ID: 19958212
[TBL] [Abstract][Full Text] [Related]
14. Modeling patient empowerment and health literacy to glycemic control in insulin-treated patients: A prospective study.
Wang RH; Hsu HC; Chen SY; Hsieh CH; Lee YJ
Patient Educ Couns; 2019 Jul; 102(7):1336-1341. PubMed ID: 30773291
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of insulin initiation on resource utilization and direct costs of treatment over 12 months in patients with type 2 diabetes in Europe: results from INSTIGATE and TREAT observational studies.
Brismar K; Benroubi M; Nicolay C; Schmitt H; Giaconia J; Reaney M
J Med Econ; 2013 Aug; 16(8):1022-35. PubMed ID: 23738910
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and treatment costs of type 2 diabetes in Germany and the effects of social and demographical differences.
Sittig DT; Friedel H; Wasem J
Eur J Health Econ; 2015 Apr; 16(3):305-11. PubMed ID: 24619251
[TBL] [Abstract][Full Text] [Related]
17. Incidence and costs of hypoglycemia in insulin-treated diabetes in Switzerland: A health-economic analysis.
Tzogiou C; Wieser S; Eichler K; Carlander M; Djalali S; Rosemann T; Brändle M
J Diabetes Complications; 2023 Jun; 37(6):108476. PubMed ID: 37141836
[TBL] [Abstract][Full Text] [Related]
18. Drug usage patterns and treatment costs in newly-diagnosed type 2 diabetes mellitus cases, 2007 vs 2012: findings from a large US healthcare claims database analysis.
Weng W; Liang Y; Kimball ES; Hobbs T; Kong S; Sakurada B; Bouchard J
J Med Econ; 2016 Jul; 19(7):655-62. PubMed ID: 26855139
[TBL] [Abstract][Full Text] [Related]
19. Use of healthcare resources and costs associated to the start of treatment with injectable drugs in patients with type 2 diabetes mellitus.
Sicras-Mainar A; Navarro-Artieda R; Morano R; Ruíz L
Endocrinol Nutr; 2016 Dec; 63(10):527-535. PubMed ID: 27744013
[TBL] [Abstract][Full Text] [Related]
20. Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study.
Balkrishnan R; Rajagopalan R; Camacho FT; Huston SA; Murray FT; Anderson RT
Clin Ther; 2003 Nov; 25(11):2958-71. PubMed ID: 14693318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
